Pfizer, Innovent sign $10.5B cancer drug pact

Pfizer Inc. (PFE) and Innovent Biologics have announced a global strategic licensing and collaboration agreement focused on a portfolio of 12 early-stage and de novo oncology programs. The portfolio includes antibody-drug conjugates with novel payloads and multispecific immune-engaging antibodies, underscoring both companies’ push into next-generation cancer therapeutics.

The deal is structured around a broad research and development partnership, with Pfizer and Innovent combining discovery and early clinical capabilities. The collaboration reflects a shared intent to expand potential treatment options across multiple cancer indications using emerging biologic modalities.

Under the agreement, Innovent will receive a $650 million upfront payment from Pfizer. In addition, Innovent is eligible for up to $9.85 billion in development, regulatory and commercial milestone payments tied to the progress and performance of the programs covered by the collaboration.

Innovent is also entitled to up to double-digit royalties on sales of any approved products arising from the portfolio. Taken together, the upfront payment, potential milestones and royalties give the transaction a stated total potential value of up to $10.5 billion.

The portfolio consists of 12 programs, combining assets at different stages of early development and discovery. Eight of the programs are Innovent-originated early-stage candidates, while four are Pfizer-proposed discovery programs that will be advanced within the collaboration framework.

The programs encompass antibody-drug conjugates and multispecific immune-engaging antibodies, with an emphasis on novel payload technologies and immune mechanisms. The mix of Innovent-originated and Pfizer-proposed assets is designed to create a diversified pipeline under the joint effort.

The agreement includes a multi-layered global rights structure. Pfizer will obtain an exclusive global license to four of the programs in the portfolio. For another four programs, Pfizer will receive an exclusive license outside Greater China, while Innovent retains rights in that territory.

The remaining four programs will be co-developed by Pfizer and Innovent, with the companies sharing development costs. For these co-developed assets, Innovent will keep rights in Greater China, and the two firms will co-commercialize and share profits in the United States and Europe.

Innovent will lead development activities for the portfolio through Phase 1 clinical trials. Following completion of Phase 1, Pfizer will assume responsibility for future global development for the programs covered by the collaboration.

Both companies stated that the transaction is expected to close in the third quarter, subject to the fulfillment of required regulatory approvals. The closing timeline and subsequent development transition are key steps for moving the 12 oncology programs further into the clinic and, potentially, toward commercialization.